Oramed forms joint venture to develop oral COVID-19 vaccines with POD delivery tech

Oramed Pharmaceuticals (NSDQ:ORMP) announced today that it is forming a joint venture to develop novel oral COVID-19 vaccines.

New York-based Oramed entered into definitive agreements to form Oravax Medical, which is based on Oramed’s proprietary POD (protein oral delivery) technology and Premas Biotech’s novel vaccine technology, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0